ClinicalTrials.gg
RecruitingNCT07527923AURA-ADUpdated Nov 6, 2026

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

A Phase 1 interventional study of REGN20423 and Placebo in Healthy Volunteer and Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals. Recruiting at 9 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Nov 6, 2026First site in United StatesPrimary completion moved+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals — 1 open to participants now, 2 under way, none of them phase 3. Dermatitis, Atopic · Regeneron Pharmaceuticals.

Planned enrollment
15th of 25
160 · median 194
Started
2026
the only one that year
Phase 1
4 of 30
1 open now
Registered
30th of 30
by date

Among the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals, this one is the 15th largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2026, is one of 4 in phase 1, and was the 30th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

1 of the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals is open now, in 2 countries.

By country, each count listing its studies:

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals, or all of them as a file.
02

Study summary

This study will test an experimental study medicine called REGN20423 to see how effective it is in healthy participants (in Part A) and participants with atopic dermatitis (eczema) (in Part B). REGN20423 is a study medicine that is only used in clinical studies. REGN20423 has not previously been studied in humans.

The study is looking at:

  • What side effects REGN20423 might cause
  • How much REGN20423 is in the blood at different times
  • How well REGN20423 works in adults with atopic dermatitis
  • Whether the body makes antibodies against REGN20423
  • How the body changes after having REGN20423, which can help researchers understand why REGN20423 works better in some people than others
  • What the best dose of REGN20423 is
03

Conditions studied

  • Healthy Volunteer
  • Atopic Dermatitis

Keywords

  • Eczema
  • Inflammatory skin disease
04

Who can participate

The criteria were revised on the registry on Nov 6, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Part A: Enrolls healthy participants Part B: Enrolls participants with atopic dermatitis

Key Inclusion Criteria:

Part A:

  1. Maximum age of 65 years of age (Part A Only)
  2. Is judged by the investigator to be in good health based on medical history, physical examination, vital signs, (ECGs), and laboratory safety testing at screening and prior to initial dose of study intervention
  3. Has a within 18 to 31 kg/m² (inclusive) at the screening visit

    Part B:

  4. Has a history of AD for at least 6 months at screening
  5. Has EASI score ≥5 at both the screening and baseline visits
  6. Has IGA score ≥2 at both the screening and baseline visits

Key Exclusion Criteria

Part A:

  1. Hospitalized (>24 hours) for any reason within 30 days prior to the screening visit
  2. to the study treatment or any of its
  3. History of clinical parasite infection, except treated trichomoniasis
  4. Received a within 1 month prior to the first screening visit or anticipates need for a live attenuated vaccine during the study
  5. History of alcohol or drug abuse as determined by the investigator

    Part B:

  6. Known or suspected history of
  7. Presence of skin comorbidities at screening that may interfere with study assessments
  8. Inability to discontinue medications and treatments prior to baseline and during the study per the Excluded Medications and Treatments list
  9. Uncontrolled chronic disease that might require bursts of oral during the study

Note: Other protocol defined Inclusion/ Exclusion criteria apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Part A

    Drug: REGN20423 · Other: Placebo

  • Experimental
    Part B

    Drug: REGN20423 · Other: Placebo

Interventions

  • DrugREGN20423

    Administered per the protocol

  • OtherPlacebo

    Administered per the protocol

06

What researchers measure

Primary outcomes

  1. Occurrence of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Up to 69 weeks

  2. Severity of TEAEs

    Time frame: Up to 69 weeks

Secondary outcomes

  1. Concentrations of REGN20423 in serum

    Time frame: Up to 57 weeks

  2. Absolute values from baseline of total Interleukin 13 (IL-13)

    Time frame: Up to 52 weeks

  3. Absolute values from baseline of total Immunoglobulin E (IgE)

    Time frame: Up to 52 weeks

  4. Absolute values from baseline of total eosinophil counts in blood

    Time frame: Up to 52 weeks

  5. Absolute values from baseline of total periostin

    Time frame: Up to 52 weeks

  6. Absolute values from baseline of total Thymus and Activation-Regulated Chemokine (TARC)

    Time frame: Up to 52 weeks

  7. Percent change from baseline of total IL-13

    Time frame: Up to 52 weeks

  8. Percent change from baseline of total IgE

    Time frame: Up to 52 weeks

  9. Percent change from baseline of total eosinophil counts in blood

    Time frame: Up to 52 weeks

  10. Percent change from baseline of total periostin

    Time frame: Up to 52 weeks

  11. Percent change from baseline of total TARC

    Time frame: Up to 52 weeks

  12. Occurrence of Anti-Drug Antibodies (ADA) to REGN20423

    Time frame: Up to 57 weeks

  13. Magnitude of ADA to REGN20423

    Time frame: Up to 57 weeks

  14. Absolute change from baseline in Eczema Area and Severity Index (EASI) score

    Part B EASI is a validated measure used to assess the severity and extent as a percentage by body area of head, trunk, arms and legs, and converted to a score of 0 to 6. Higher scores indicate higher improvement. Also, AD disease characteristics will be assessed for severity by the investigator or designee on a scale of "0" (absent) through "3" (severe)

    Time frame: Up to 52 weeks

  15. Percent change from baseline in EASI score

    Part B

    Time frame: Up to 52 weeks

  16. Achievement of EASI-50

    Part B

    Time frame: Up to 52 weeks

  17. Achievement of EASI-75

    Part B

    Time frame: Up to 52 weeks

  18. Achievement of EASI-90

    Part B

    Time frame: Up to 52 weeks

  19. Achievement of Investigator's Global Assessment (IGA) 0-1

    Part B IGA is a frequently used clinician-reported instrument in clinical studies for rapid and easy assessment of disease severity of AD globally. It is based on a 5-point scale with range from "0" (clear) to "4" (severe), with higher scores indicating more severe disease

    Time frame: Up to 52 weeks

  20. Achievement of IGA 0-1 with reduction in IGA score by ≥2

    Part B

    Time frame: Up to 52 weeks

  21. Achievement of a reduction in IGA score by ≥2

    Part B

    Time frame: Up to 52 weeks

  22. Absolute change from baseline in % Body Surface Area (BSA)

    Part B

    Time frame: Up to 52 weeks

  23. Absolute change from baseline in EASI

    Part B

    Time frame: Up to 52 weeks

  24. Percent change from baseline in % BSA

    Part B

    Time frame: Up to 52 weeks

  25. Percent change from baseline in EASI

    Part B

    Time frame: Up to 52 weeks

07

Study locations

9 of 9 sites recruiting
  • Cahaba Dermatology & Skin Health Center, LLC
    Birmingham, Alabama 35244, United States
    Recruiting
  • Arkansas Research Trials
    North Little Rock, Arkansas 72117, United States
    Recruiting
  • Alliance Clinical, Focus Clinical Research
    West Hills, California 91307, United States
    Recruiting
  • Florida International Research Center
    Miami, Florida 33173, United States
    Recruiting
  • Encore Medical Research of Weston LLC
    Weston, Florida 33331, United States
    Recruiting
  • Rophe Adult and Pediatric Medicine
    Union City, Georgia 30291, United States
    Recruiting
  • National Allergy and Asthma Research, LLC
    North Charleston, South Carolina 29420, United States
    Recruiting
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
    Recruiting
  • Center for Clinical Pharmacology University Hospitals Leuven (UZ Leuven)
    Leuven, Vlaams-Brabant 3000, Belgium
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Aug 2028, 26 months after the start.

Of 114 industry-sponsored phase 1 interventional studies under Dermatitis, Atopic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's planned 26 months is above that.

Counting every sponsor, half of 131 studies reached it within 13 months; a quarter within 5 and three quarters within 20.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Jun 2028 → Aug 2028 and completion Jun 2028 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 14, 2026
StartActual
May 22, 2026
Primary completionEst.
Aug 14, 2028was Jun 2028
CompletionEst.
Aug 14, 2028was Jun 2028
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added, 1 site removed — first site in United States
Show 9 added (9 United States)
  • Cahaba Dermatology & Skin Health Center, LLC · Birmingham, United States
  • Alliance Clinical West Hills (Focus Clinical Research) · West Hills, United States
  • National Allergy and Asthma Research, LLC · North Charleston, United States
  • Texas Dermatology and Laser Specialists · San Antonio, United States
  • Arkansas Research Trials · North Little Rock, United States
  • Florida International Research Center · Miami, United States
  • Alliance Clinical, Focus Clinical Research · West Hills, United States
  • Encore Medical Research of Weston LLC · Weston, United States
  • Rophe Adult and Pediatric Medicine · Union City, United States
Show 1 removed
  • Alliance Clinical West Hills (Focus Clinical Research) · West Hills, United States
across 3 updates, Sep 25, 2026 – Nov 6, 2026
Primary completion
Jun 23, 2028→Aug 14, 2028
Nov 6, 2026
Study completion
Jun 23, 2028→Aug 14, 2028
Nov 6, 2026
Enrollment
144→160
Nov 6, 2026
Eligibility
1 criterion added
What changed in the criteria
  • AddedMaximum age of 65 years of age (Part A Only)
Nov 6, 2026
Show all 3 updates
  1. Nov 6, 2026
    3 sites added, 1 site removed
    Show 3 added (3 United States)
    • Alliance Clinical, Focus Clinical Research · West Hills, United States
    • Encore Medical Research of Weston LLC · Weston, United States
    • Rophe Adult and Pediatric Medicine · Union City, United States
    Show 1 removed
    • Alliance Clinical West Hills (Focus Clinical Research) · West Hills, United States
    Primary completion Jun 23, 2028→Aug 14, 2028
    Study completion Jun 23, 2028→Aug 14, 2028
    Enrollment 144→160
    Eligibility 1 criterion added
    What changed in the criteria
    • AddedMaximum age of 65 years of age (Part A Only)
    + 1 other change: description
  2. Oct 7, 2026
    2 sites added
    Show 2 added (2 United States)
    • Arkansas Research Trials · North Little Rock, United States
    • Florida International Research Center · Miami, United States
    + 1 other change: verification date
  3. Sep 25, 2026
    4 sites added — first site in United States
    Show 4 added (4 United States)
    • Cahaba Dermatology & Skin Health Center, LLC · Birmingham, United States
    • Alliance Clinical West Hills (Focus Clinical Research) · West Hills, United States
    • National Allergy and Asthma Research, LLC · North Charleston, United States
    • Texas Dermatology and Laser Specialists · San Antonio, United States
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07527923
Responsible party
Sponsor
First posted
Apr 14, 2026
Start date
May 22, 2026
Primary completion
Aug 14, 2028 (estimated)
Completion
Aug 14, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion